This site is intended only for healthcare professionals resident in the Republic of Ireland

Search

Menu

Close

Sign in or RegisterLog out
Our medicinesTherapy areasExplore contentExplore contentMaterialsVideosPodcastsLet’s connectLet's connectContact usSign up

Menu

Close

AboutTherapeutic IndicationsRheumatoid arthritisJuvenile idiopathic arthritisPsoriatic arthritisAxial spondyloarthritisPlaque psoriasis & Paediatric plaque psoriasisMechanism of actionMechanism of actionDosingDosingRheumatoid arthritis, psoriatic arthritis & axial spondyloarthritisJuvenile idiopathic arthritisPlaque psoriasisPaediatric plaque psoriasisAdministration & storageAdministrationMYCLIC®StorageEfficacy & SafetyEfficacy & SafetyRheumatoid arthritisAxial spondyloarthritisPsoriatic arthritisPlaque psoriasisJuvenile idiopathic arthritisSupport & ResourcesMaterials
DosingRheumatoid arthritis, psoriatic arthritis & axial spondyloarthritis

Dosing with Enbrel® can be individualised based on the needs of each patient1​​​​​​​

Patients treated with Enbrel should be given the Patient Card.

The recommended dose of Enbrel for adult patients with RA, PsA and axSpA (AS or nr-AxSpA) is:1​​​​​​​

  • 25 mg twice weekly, or
  • 50 mg once weekly

In patients with PsA and axSpA (AS or nr-AxSpA), available data suggest that a clinical response is usually achieved within 12 weeks of treatment. Continued therapy should be carefully reconsidered in patients not responding within this time period1

Dosing options adapted from Enbrel Summary of Product Characteristics1AS: Ankylosing spondylitis; axSpA: Axial spondyloarthritis; nr-AxSpA: Non-radiographic axial spondyloarthritis; PsA: Psoriatic arthritis; RA: Rheumatoid arthritis.Explore more Efficacy & Safety

Learn more about the efficacy and safety of Enbrel in RA

 Learn more Dosing Support & Resources

Pfizer has resources available to support you and your Enbrel patients

 Explore

Legal Category: S1A
Further information is available upon request

PP-ENB-IRL-0270 May 2023

Adverse events should be reported. Report an adverse event to your national reporting system (HPRA Pharmacovigilance)
 

Adverse events should also be reported to Pfizer Medical Information on 1800 633 363

PfizerPro AccountPfizerPro Account

Please sign in or register to gain access to information relating to Pfizer medicines and vaccines, medical conditions, patient materials and services.

Sign in or RegisterRegisterAccountLog out

This site is intended only for healthcare professionals resident in the Republic of Ireland. If you are a member of the public wishing to access information on a specific medicine, please visit https://www.medicines.ie

 

This website is brought to you by Pfizer Healthcare Ireland, 9 Riverwalk, National Digital Park, Citywest Business Campus, Dublin 24, Ireland. Registered in the Republic of Ireland No. 127002.

 

Copyright © 2023 Pfizer Limited. All rights reserved.

PP-UNP-IRL-0176. January 2023
For Healthcare Professionals in the Republic of Ireland *

The information contained on this site is reserved exclusively for healthcare professionals resident in the Republic of Ireland.

I confirm that I am a healthcare professional resident in the Republic of Ireland.*

I accept and agree to the terms of use.*

If you select 'No', you will be redirected to Pfizer.ie, where you will be able to access information on Pfizer Healthcare Ireland.

PP-UNP-IRL-0176. January 2023

Yes No
You are now leaving PfizerPro
You are now leaving PfizerPro Ireland. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer. Pfizer accepts no responsibility for the content or services of the linked site.
PP-UNP-IRL-0176. January 2023